Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zamifenacin SCHEMBL311829 | 1.00 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL4603503 | 0.99 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL8938193 | 0.93 | KDM4E (0.45) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL3227612 | 0.93 | KDM4E (0.45) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL13957310 | 0.92 | SLC6A2 (0.41) | ADRA1DADRA1AADRA1BMAPK1MCHR1 | |
| Zamifenacin SCHEMBL13957195 | 0.92 | SLC6A2 (0.41) | ADRA1DADRA1AADRA1BMAPK1MCHR1 | |
| Zamifenacin SCHEMBL13957205 | 0.91 | NOS2 (0.42) | ADRA1DADRA1AADRA1BMEN1MAPK1 | |
| SCHEMBL8938462 | 0.90 | KCNH2 (0.44) | ADRA1DADRA1AADRA1BKDM4ENOS2 | |
| Zamifenacin SCHEMBL13957196 | 0.90 | ADRA1D (0.45) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL13957218 | 0.90 | NOS2 (0.41) | ADRA1DADRA1AADRA1BKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3139924-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | Visco, Anthony G. (US) | 2017-03-15 | — | — | EP | claimed |
| WO-2015171753-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | VISCO ANTHONY G (US) | 2015-11-12 | — | — | WO | claimed |
| US-20200163951-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2011069156-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ODORANT RECEPTOR ACTIVITY | DUKE UNIVERSITY (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20090005309-A1 | SUBSTITUTED PIPERIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005309-A1 | SUBSTITUTED PIPERIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005309-A1 | SUBSTITUTED PIPERIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008144602-A1 | DEUTERATED ZAMIFENACIN DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144602-A1 | DEUTERATED ZAMIFENACIN DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-5534626-A | SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST INTERMEDIATES | PFIZER INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5410046-A | Selective muscarinic receptor antagonists | PFIZER INC. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5231104-A | Anticholinergic | PFIZER INC. (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0350309-B1 | PIPERIDINE DERIVATIVES | Pfizer Limited (GB) | 1992-11-11 | — | — | EP | disclosed |
| US-5089505-A | Anticholinergic agents | PFIZER INC. (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0350309-A1 | Piperidine derivatives | Pfizer Limited (GB) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005309-A1 | SUBSTITUTED PIPERIDINES | CHRM3, CHRM2, CHRM5 | ADRA1D 12/4885ADRA1A 18/4885ADRA1B 10/4885 |
| US-20200163951-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | ADRA1D 99/4885ADRA1A 74/4885ADRA1B 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.